The results show that none of the employed combinations of two different inhibitors of ACSL4, LOX-5 and COX-2 produced a synergistic inhibition on cell proliferation and migration of MDA-MB-231 breast cancer cells (Table 1). The gene discussed is ACSL4; the disease is breast cancer.